The Sapien M3 device is the first approved mitral regurgitation treatment to use a transseptal approach, Edwards said.
Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the ...
Zacks Investment Research on MSN
EW wins FDA approval for SAPIEN M3 as first transseptal TMVR therapy
Edwards Lifesciences EW announced that the FDA approved its SAPIEN M3 transcatheter mitral valve replacement system, making ...
First-of-its-kind Edwards SAPIEN M3 transcatheter mitral valve system secures FDA approval for transseptal mitral ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...
Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first ...
Edwards Lifesciences Corp. won FDA approval for its Sapien 3 transcatheter heart valve device for aortic and mitral valve-in-valve procedures. The Irvine, Calif.-based company leads the way in a ...
Hoag Memorial Hospital Presbyterian in Newport Beach will be among one of the first U.S. hospitals to offer a much-touted medical device from a device maker here. Irvine-based Edwards Lifesciences ...
August 18, 2010 (Montreal, Quebec and Leicester, United Kingdom) — The best way to ensure that a patient who meets criteria for undergoing transcatheter aortic-valve replacement actually ends up ...
Irvine-based Edwards Lifesciences Corp. said today that the Food and Drug Administration approved its Edwards Sapien XT replacement heart valve for aortic valve-in-valve procedures. Valve-in-valve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback